ArticleThe Journal of rheumatology2021
National Sjögren's Foundation Survey: Burden of Oral and Systemic Involvement on Quality of Life.
Article in The Journal of rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease.Arthritis care & research · 2026Guideline
- Low-Density Granulocytes Link to Disease Activity, Organ Involvement, and Cytokine Production in Sjögren's Disease.International journal of molecular sciences · 2026Article
- Health-Related Quality of Life in Primary Sjögren's Syndrome: Oral Manifestations and Patient-Reported Outcomes.Dentistry journal · 2026Article
- Reconsidering the role of dentistry in managing Sjögren disease: Insights from The National Dental Practice-Based Research Network findings.Journal of the American Dental Association (1939) · 2026Article
- Oral Manifestations of Sjögren's Syndrome: Recognition, Management, and Interdisciplinary Care.Medicina (Kaunas, Lithuania) · 2025Review
- Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study).Frontiers in medicine · 2025Article
- Brazilian version of the "Primary Sjögren's Syndrome - Quality of Life questionnaire (PSS-QoL)": translation, cross-cultural adaptation and validation.Advances in rheumatology (London, England) · 2024Article
- Update on the pathophysiology and treatment of primary Sjögren syndrome.Nature reviews. Rheumatology · 2024Review
- [Update on Sjögren's syndrome : Diagnostics, treatment, and challenges].Zeitschrift fur Rheumatologie · 2024Article
- The experience of dry mouth and screening for Sjogren's syndrome by the dentist: patient-reported experiences.BMC oral health · 2023Article
- Symptom-Based Cluster Analysis Categorizes Sjögren's Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance.Arthritis & rheumatology (Hoboken, N.J.) · 2022Article
- A comprehensive overview of living with Sjögren's: results of a National Sjögren's Foundation survey.Clinical rheumatology · 2022Review
- State of the art and future directions in assessing the quality of life in rare and complex connective tissue and musculoskeletal diseases.Frontiers in medicine · 2022Review
- Impact of the COVID-19 pandemic on eye strain and dry eye symptoms.The ocular surface · 2021Article
- Instruments for Outcome Evaluation of Specific Domains in Primary Sjögren's Syndrome.Biomolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo define the association between oral and systemic manifestations of Sjögren syndrome (SS) and quality of life (QOL).
methodsWe analyzed a cross-sectional survey conducted by the Sjögren's Foundation in 2016, with 2961 eligible responses. We defined oral symptom and sign exposures as parotid gland swelling, dry mouth, mouth ulcers/sores, oral candidiasis, trouble speaking, choking or dysphagia, sialolithiasis or gland infection, and dental caries. Systemic exposures included interstitial lung disease, purpura/petechiae/cryoglobulinemia, vasculitis, neuropathy, leukopenia, interstitial nephritis, renal tubular acidosis, autoimmune hepatitis, primary biliary cholangitis, or lymphoma. Outcomes included SS-specific QOL questions generated by SS experts and patients.
resultsUsing multivariable regression models adjusted for age, sex, race, and employment, we observed that mouth ulcers or sores, trouble speaking, and dysphagia were associated with poor quality of life. The following oral aspects had the greatest effect on the following QOL areas: (1) mouth ulcers/sores on the challenge and burden of living with SS (OR 4.26, 95% CI 2.89-6.28); (2) trouble speaking on memory and concentration (OR 4.24, 95% CI 3.28-5.48); and (3) dysphagia on functional interference (OR 4.25, 95% CI 3.13-5.79). In contrast, systemic manifestations were associated with QOL to a lesser extent or not at all.
conclusionOral manifestations of SS, particularly mouth ulcers or sores, trouble speaking, and dysphagia, were strongly associated with worse QOL. Further study and targeted treatment of these oral manifestations provides the opportunity to improve quality of life in patients with SS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.